What should we do about overweight and obesity?
Author: Ian D Caterson
Published online: 6 December 1999
|
The Weight Debate What should we do about overweight and obesity? The goals of treatment should not necessarily be to normalise weight, but to optimise health |
![]() MJA 1999; 171: 599-600 |
|
Introduction -
Why are we getting obese? -
Why have we not been effective in treating obesity? -
What should we do about obesity? -
What has been ignored is our environment
| |
References
- McLennan W, Podger A. National Nutrition Survey -- Selected Highlights Australia. Canberra: Australian Bureau of Statistics and Department of Health and Family Services, 1997.
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity, Geneva, 3-5 June, 1997. WHO: Geneva, 1997.
- National Health and Medical Research Council. Acting on Australia's weight. The Report of the NHMRC Working Party on the prevention of overweight and obesity. Canberra: NHMRC, 1996.
- Dupen F, Bauman A, Lin R. The source of risk factor information for general practitioners: is physical activity under-recognised? Med J Aust 1999; 171: 601-603.
- Physical activity and health: a report of the Surgeon General. Atlanta, Md: US Department of Health and Human Services, Centers for Disease Control, 1996.
- National Physical Activity Guidelines for Australians. Canberra: Commonwealth Department of Health and Aged Care, 1999.
- Wing RR, Greeno CG. Behavioural and psychosocial aspects of obesity. Clin Endocrinol Metab 1994; 8: 689-703.
- Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non- prescription weight loss supplements. Med J Aust 1999; 171: 604-608.
- Burry JN. Obesity and virtue. Is staying lean a matter of ethics? Med J Aust 1999; 171: 609-610.
- Proietto J. Why staying lean is not a matter of ethics. Med J Aust 1999; 171: 611-613.
- Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1991; 16: 397-415.
- Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
- McNeely W, Goa KL. Sibutramine. A review of its contribution to management. Drugs 1998; 56: 1093-1124.
- Egger G, Swinburn B. An "ecological" approach to the obesity pandemic. BMJ 1997; 315: 477-480.
When ‘Liver Enzymes’ Are Not Hepatic: Late-Onset Pompe Disease
Shauna Madigan, Georgina England, Wayne Rankin
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
The early implementation phase of the Omega‐3 Test‐and‐Treat Program for reducing the risk of preterm birth, South Australia, 2021–22: an implementation evaluation study
Karen P Best, Celine Northcott, Lucy A Simmonds, Philippa Middleton, Lisa N Yelland, Vanessa Moffa, Khoa Lam, Penelope Coates, Cornelia Späth, Carol WK Siu, Karen Glover, Rhiannon Smith, Robert Gibson, Maria Makrides
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
The role of GLP‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system
Deshan Sebaratnam, Jessie T Lu, Helen Y Sun
